Pender Fund Capital Management Ltd. Esperion Therapeutics, Inc. Call Options Transaction History
Pender Fund Capital Management Ltd.
- $154 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
184Shares Held
111MCall Options Held
96.7KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$18.5 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$17.8 Million0.18% of portfolio
-
Morgan Stanley New York, NY6.59MShares$11.8 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $119M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...